Ardelyx, Inc.

NASDAQ:ARDX

Biotechnology

Healthcare
$3.06 -1.03%

-$0.06 today

Market cap
$769.20M
Beta
0.58
P/E (TTM)
-24.5
EPS (TTM)
-$0.24
52W Low $3.49High $8.40

Volume 3.39M

Average 3.58M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$42.48M

FY 2025 · Annual

Investing Cash Flow

-$8.96M

FY 2025 · Annual

Financing Cash Flow

$54.51M

FY 2025 · Annual

-48.9% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(158.17M)(67.21M)(66.07M)(39.14M)(61.6M)
Depreciation & Amortization1.44M1.14M1.29M2.06M3.06M
Deferred Income Tax(190K)0000
Stock-Based Compensation12.04M10.75M13.53M37.38M48.96M
Change in Working Capital(11.92M)(19.58M)(43.39M)(49.17M)(31.35M)
Accounts Receivables(502K)(7.23M)(14.3M)(35.67M)(14.14M)
Inventory(10.37M)(28.35M)(21.14M)(41.7M)(31.92M)
Accounts Payables(1.35M)6.58M279K4.86M3.24M
Other Working Capital300K9.42M(8.23M)23.34M11.48M
Other Non-Cash Items4.25M4.84M4.91M4.05M(1.55M)
Operating Cash Flow(152.55M)(70.04M)(89.72M)(44.81M)(42.48M)
Capital Expenditures(1.87M)(55K)(344K)(1.01M)(1.49M)
Acquisitions (Net)(52.82M)0000
Purchases of Investments(72.74M)(50.33M)(215.23M)(195.16M)(218.92M)
Sales of Investments125.55M67M84.32M177.85M211.46M
Other Investing Activities52.82M1.8M000
Investing Cash Flow50.95M18.42M(131.25M)(18.32M)(8.96M)
Debt Repayment(19.44M)(6.07M)22.39M99.45M48.67M
Common Stock Issued101.15M71.63M119.24M8.14M5.84M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.3M9.78M4.67M(1M)0
Financing Cash Flow83M75.34M146.3M106.59M54.51M
Effect of Forex Changes00000
Net Change in Cash(18.6M)23.71M(74.67M)43.46M3.07M
Free Cash Flow(154.42M)(70.1M)(90.06M)(45.82M)(43.98M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$61.6M
+ D&A$3.1M
+ Stock-Based Comp$49.0M
+ Deferred Tax$0
- Working Capital-$31.4M
- Other Non-Cash-$1.6M
= Operating Cash Flow-$42.5M
- Capex-$1.5M
= Free Cash Flow-$44.0M

Analysis

FY2025 free cash flow is -$44.0M. FCF conversion is 71.4% of net income. Operating cash flow was -$42.5M, with capex of -$1.5M. The largest bridge item is Stock-Based Comp at $49.0M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
10-QQuarterly reportNov 3, 2026
8-KCurrent reportNov 3, 2026
4Statement of changes in beneficial ownershipAug 25, 2026
4Statement of changes in beneficial ownershipAug 25, 2026
4Statement of changes in beneficial ownershipAug 25, 2026

Does ARDX generate free cash flow?

Ardelyx, Inc. (ARDX) generated -$43.98M of free cash flow in fiscal 2025.

How much operating cash flow does ARDX produce?

Operating cash flow was -$42.48M, before capital expenditures of $1.49M.